Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: Comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort

Journal of the American Heart Association

Volumn 4, Issue 4, 2015, Pages

  Andersson, Charlotte ^a,e   Enserro, Danielle ^a,b   Larson, Martin G ^a,b,c   Xanthakis, Vanessa ^a,c,d   Vasan, Ramachandran S ^a,c,d  

^a FRAMINGHAM HEART STUDY   (United States)

^b USA   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Primary prevention; Risk prediction; Statin

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; SEX DIFFERENCE; UNITED STATES; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; STROKE;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STROKE; UNITED STATES;

EID: 84966401190     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.001888     Document Type: Article

References (19)

1. Krumholz HM. The new cholesterol and blood pressure guidelines: perspective on the path forward. JAMA. 2014;311:1403-1405.
2. D'Agostino RB Sr, Ansell BJ, Mora S, Krumholz HM. Clinical decisions. The guidelines battle on starting statins. N Engl J Med. 2014;370:1652-1658.
3. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Tomaselli GF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;129:S1-S45.
4. Muntner P, Safford MM, Cushman M, Howard G. Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation. 2014;129:266-267.
5. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382:1762-1765.
6. Raymond C, Cho L, Rocco M, Hazen SL. New cholesterol guidelines: worth the wait Cleve Clin J Med. 2014;81:11-19.
7. GoffDC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Tomaselli GF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49-S73.
8. Report on the assessment of cardiovascular risk: full work group report supplement. Available at: http://jaccjacc.cardiosource.com/acc_documents/2013_FPR_S5_Risk_Assesment.pdf. Accessed March 25, 2015.
9. Kavousi M, Leening MJ, Nanchen D, Greenland P, Graham IM, Steyerberg EW, Ikram MA, Stricker BH, Hofman A, Franco OH. Comparison of application of the ACC/AHA guidelines, adult treatment panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311:1416-1423.
10. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
11. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, Williams K, Neely B, Sniderman AD, Peterson ED. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422-1431.
12. Muntner P, Colantonio LD, Cushman M, GoffDC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406-1415.
13. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
14. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.
15. Karmali KN, GoffDC Jr, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:959-968.
16. Andersson C, Vasan RS. Is there a role for coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease? Clinical risk scores are sufficient to define primary prevention treatment strategies among asymptomatic patients. Circ Cardiovasc Imaging. 2014;7:390-397; discussion 397.
17. Blaha MJ, Silverman MG, BudoffMJ. Is there a role for coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease?: clinical risk scores are not sufficient to define primary prevention treatment strategies among asymptomatic patients. Circ Cardiovasc Imaging. 2014;7:398-408; discussion 408.
18. Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. JAMA Intern Med. 2014;174:1964-1971.
19. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-590.